Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122447 · ClinicalTrials.gov registry record · NA
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
NCT00122447: Completed NA study, sponsored by Emory University.
NCT00122447 is a NA study that has completed, run by Emory University. The registered enrollment target is 84 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00122447, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
Primary Outcome
Surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG Olmesartan
- DRUG Alpha lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-05 |
| Phase | NA |
What the finished NCT00122447 record still lists
NCT00122447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00122447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00122447 about?
NCT00122447 is a clinical study titled "Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance". The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in ...
What is the current status of trial NCT00122447?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2005-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00122447?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), Olmesartan (DRUG), Alpha lipoic acid (DRUG).
Who is sponsoring clinical trial NCT00122447?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00122447's enrollment target sits among peer trials
84 983rd of 2000 higher than 1,011 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia